Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Deferred Taxes: 2009-2024

Historic Deferred Taxes for Lifecore Biomedical (LFCR) over the last 16 years, with Nov 2024 value amounting to $109,000.

  • Lifecore Biomedical's Deferred Taxes rose 372.50% to $109,000 in Q4 2024 from the same period last year, while for Nov 2024 it was $136,000, marking a year-over-year decrease of 66.50%. This contributed to the annual value of $163,000 for FY2024, which is 54.34% down from last year.
  • Per Lifecore Biomedical's latest filing, its Deferred Taxes stood at $109,000 for Q4 2024, which was up 209.00% from -$100,000 recorded in Q3 2024.
  • Lifecore Biomedical's Deferred Taxes' 5-year high stood at $2.4 million during Q2 2020, with a 5-year trough of -$5.3 million in Q1 2020.
  • In the last 3 years, Lifecore Biomedical's Deferred Taxes had a median value of -$6,500 in 2022 and averaged -$111,000.
  • Data for Lifecore Biomedical's Deferred Taxes shows a peak YoY increase of 559.73% (in 2020) and a maximum YoY decrease of 1,774.20% (in 2020) over the last 5 years.
  • Lifecore Biomedical's Deferred Taxes (Quarterly) stood at -$2.4 million in 2020, then dropped by 17.58% to -$2.8 million in 2021, then spiked by 100.14% to $4,000 in 2022, then slumped by 1,100.00% to -$40,000 in 2023, then skyrocketed by 372.50% to $109,000 in 2024.
  • Its Deferred Taxes stands at $109,000 for Q4 2024, versus -$100,000 for Q3 2024 and -$64,000 for Q2 2024.